Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023

Author's Avatar
Jun 07, 2023

– Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV –